KKKoji Kinoshita

Koji Kinoshita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koji Kinoshita has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renal function–adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study

    by Daisuke Tomita, Yuji Nozaki, Rika Fukuda, Yumi Morimoto, Hirotaka Yamazawa, Kaori Ishimura, Chisato Ashida, Tetsu Itami, Toshihiko Shiga, Wataru Yamamoto, et al.

  • Open Access

    Diagnostic performance of HScore for macrophage activation syndrome complicating Still’s disease in adults: a multicentre case–control study

    by Toshihiko Shiga, Yuji Nozaki, Saki Tsuchimoto, Hirotaka Yamazawa, Chisato Ashida, Daisuke Tomita, Tetsu Itami, Shoichi Hino, Masafumi Sugiyama, Yasuyoshi Morita, et al.

    Objectives: To validate the diagnostic performance of the HScore for Still’s disease (SD)-associated macrophage activation syndrome (MAS; SD-MAS) in adults compared with those of the HLH-2004 diagnostic criteria used with modifications (HLH-04) and the 2016 EULAR/ACR/PRINTO classification criteria for systemic juvenile idiopathic arthritis-associated MAS (MAS-2016). Methods: This multicentre case–control study, conducted at three medical centres in Japan between 2004 and 2023, enrolled patients ≥16 years with active SD and allocated them into SD without MAS and SD-MAS groups by an expert panel. For each patient, we calculated the HScore, HLH-04, MAS-2016 and modified HScore, which excluded haemophagocytosis on bone marrow aspirate. Receiver operating characteristic curve analysis was used to assess the discriminative ability of each criterion. Logistic regression analysis was performed separately for ‘model-1’ (HScore and HLH-04) and ‘model-2’ (MAS-2016 and modified HScore). Results: This study included 86 patients with SD, 25 of whom had SD-MAS. The HScore showed the best area under the curve at 0.991 (95% CI 0.977–1.000), with a cut-off value of 192 (sensitivity, 96.0%; specificity, 96.7%). The optimal cut-off for the modified HScore was 171 (sensitivity, 92.0%; specificity, 83.6%). Multivariate analysis identified only the HScore in model-1 [odds ratio (OR) 1.271; 95% CI 1.006–1.606], whereas both MAS-2016 (OR 4.249; 95% CI 1.636–11.041) and modified HScore (OR 1.066; 95% CI 1.017–1.118) were identified in model-2. Conclusions: The HScore and modified HScore could be useful tools for diagnosing SD-MAS in adults with and without bone marrow aspiration, respectively.

  • Open Access

    Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis

    by Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, et al.

    Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.


  • Reduced versus standard dosing of Janus kinase inhibitors in rheumatoid arthritis: a propensity score–matched real-world study accounting for poor prognostic factors

    by Yuji Nozaki, Toshihiko Shiga, Jinhai Ri, Tetsu Itami, Daisuke Tomita, Hirotaka Yamazawa, Yumi Morimoto, Rika Fukuda, Takashi Tsuchimoto, Sayo Morita, et al.


  • Open Access

    Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis

    by Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, et al.

    Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited. Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort ( n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world. Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent. Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.

  • Open Access

    Urinary Kim-1 Correlates with Interstitial Nephritis Activity in Patients with Microscopic Polyangiitis

    by Chisato Ashida, Yuji Nozaki, Jinhai Li, Hiroki Akazawa, Kazuya Kishimoto, Koji Kinoshita, Itaru Matsumura

    Background: Microscopic polyangiitis (MPA) is a type of necrotizing vasculitis that primarily affects small vessels and belongs to the spectrum of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). While previous studies have identified potential prognostic biomarkers, further research is needed to validate a reliable marker for risk stratification in clinical practice. Kidney injury molecule-1 (Kim-1), a transmembrane protein expressed on proximal tubular epithelial cells, has been implicated in tubular damage. This study investigated the potential of Kim-1 as a biomarker in MPA. Methods: Kidney biopsy tissues, along with urine and blood samples, were retrospectively analyzed from 52 MPA patients and compared to urine samples from 7 healthy controls. Global disease activity was assessed using the Birmingham vasculitis activity score (BVAS) and vasculitis damage index, while renal disease activity was evaluated using renal BVAS (BVAS-R). Results: Urinary Kim-1 levels were significantly elevated in MPA patients compared to healthy controls. Urinary Kim-1 was positively correlated with the Mayo Clinic Chronicity Score (MCCS) but not with the ANCA Kidney Risk Score (AKRiS), whereas tubular Kim-1 was associated with AKRiS but not with MCCS, indicating their distinct pathological significance. Higher tubular Kim-1 expression was observed in patients with elevated BVAS-R. Urinary Kim-1 levels correlated with proteinuria and were associated with the Mayo Clinic Chronicity Score (MCCS) and ANCA Kidney Risk Score (AKRiS) but not with glomerular lesion severity. Unlike C-reactive protein (CRP), neither urinary nor tubular Kim-1 predicted MPA recurrence. Conclusions: Urinary Kim-1 reflects histopathologic findings and renal impairment but does not predict systemic disease activity or recurrence in MPA, demonstrating its potential clinical utility as a biomarker for assessing chronic renal damage.


  • Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis

    by Yuji Nozaki, Asuka Inoue, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura

    Objectives: We retrospectively evaluated the retention rate and clinical responses following treatment for rheumatoid arthritis (RA) with iguratimod (IGU) vs. salazosulfapyridine (SASP) as the first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD). Methods: We analyzed 197 RA patients who were treated with IGU or SASP as the initial treatment in the 3-year study period. The retention rate, clinical response, the dosage and percent user of prednisolone (PSL), and safety profiles were evaluated. Results: At month 36, the retention rates of the IGU and SASP groups were 52.4 vs. 32.1%. The rate of responders (good or moderate response) at month 36 was 85.8 vs. 65.2% in the IGU and SASP groups, respectively. At month 36 for the IGU and SASP groups, the percentages of PSL users were 16.7 vs. 46.7%, and the PSL dosage was 0.3 mg/d vs. 2.0 mg/d, respectively. The cumulative rates of any adverse event (AE) at month 36 were 19.8 vs. 29.2% in the IGU and SASP groups, respectively. Conclusion: IGU is a useful first-line csDMARD treatment for RA patients, showing a high retention rate and good efficacy without an increased risk of serious AEs, including serious infections. Our findings also indicate a PSL dose-sparing effect of IGU treatment.


  • Open Access

    Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment

    by Yuji Nozaki, Yasuaki Nagare, Shoichi Hino, Tomohiro Yano, Kazuya Kishimoto, Hideki Shimazu, Shinya Ikoma, Koji Kinoshita, Masanori Funauchi

    To predict the response of patients with rheumatoid arthritis (RA) to infliximab, patient profile and laboratory findings were compared to determine whether there was any association with the clinical course of the disease, and the clinical significance of serum rheumatoid factor (RF) in the response to this treatment was considered. Sixty-two RA patients were treated with infliximab, 87.9% of whom were positive for RF. At baseline and 12 months after the start of treatment, RF titers were significantly lower in the low-CRP group (CRP at 12 months1.5 mg/dl). Furthermore, at baseline and 12 months, RF titers were significantly lower in the good-CRP-response group (ΔCRP≥1.5 mg/d) compared with the poor-CRP-response group (ΔCRP≤0.3 mg/d). The percent changes in RF and CRP from baseline were correlated throughout the clinical course. The duration of disease in good-CRP-response group was shorter than that in poor-CRP-response group significantly. The rate of positivity for HLA-DR4 in good response group tends to be higher than that in poor-CRP-response group. We concluded that several factors, including disease duration, positivity for HLA-DR4, and the serum RF titer at baseline, might predict the patient response to infliximab.


  • A possible role of apoptosis for regulating autoreactive responses in systemic lupus erythematosus

    by M Funauchi, M Sugiyama, B SukYoo, S Ikoma, M Ohno, K Kinoshita, A Kanamaru

    It has been reported that apoptotic cells are increased inthe peripheral blood from patients with systemic lupuserythematosus (SLE), where dysfunctions of T helper 1 (Th1) cells are known. In order to study whether apoptosis of Th1cells is associated with the pathogenesis of SLE, earlyapoptotic cells in various T-cell subsets were detected using fluorescence-labeled annexin V (AnV). AnV binding was most frequently observed in CD4/CCR5/ T cells, andAnV binding rate (%) in this subset was higher in SLE thanin normal controls (14.7 2.6), although that in activeSLE(43.6 7.3) tended to be lower than that in inactive SLE (48.0 6.8). CD95=Fas expression was also increased i both active and inactive SLE. In some SLE patients, AnV binding rate changed in inverse proportion to titer of the serum anti-DNA antibody and in proportion to serum complement activity. These data suggest that apoptosis in Th1 cells is important in the pathogenesis of SLE and might play arole in regulating over-activation or autoreactive responses by T cells.